| ○種別 (必須): | □ | 学術論文 (審査論文)
| [継承] |
| ○言語 (必須): | □ | 英語
| [継承] |
| ○招待 (推奨): |
| ○審査 (推奨): |
| ○カテゴリ (推奨): | □ | 研究
| [継承] |
| ○共著種別 (推奨): | □ | 国内共著 (徳島大学内研究者と国内(学外)研究者との共同研究 (国外研究者を含まない))
| [継承] |
| ○学究種別 (推奨): |
| ○組織 (推奨): |
| ○著者 (必須): | 1. | (英) Nakae Kazuto (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 2. | (英) Masui Sho (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 3. | (英) Yonezawa Atsushi (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 4. | (英) Hashimoto Motomu (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 5. | (英) Watanabe Ryu (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 6. | (英) Murata Koichi (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 7. | (英) Murakami Kosaku (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 8. | (英) Tanaka Masao (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 9. | (英) Ito Hiromu (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 10. | (英) Yokoyama Kotoko (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 11. | (英) Iwamoto Noriko (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 12. | (英) Shimada Takashi (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 13. | (英) Nakamura Miyuki (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 14. | 傳田 将也 ([徳島大学.大学院医歯薬学研究部.薬学域.先端薬学教育研究プロジェクト]/[徳島大学.大学院医歯薬学研究部.薬学域.薬科学部門.創薬科学系.機能分子合成薬学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 15. | (英) Itohara Kotaro (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 16. | (英) Nakagawa Shunsaku (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 17. | (英) Ikemi Yasuaki (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 18. | (英) Imai Satoshi (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 19. | (英) Nakagawa Takayuki (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 20. | (英) Hayakari Makoto (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 21. | (英) Matsubara Kazuo (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| ○題名 (必須): | □ | (英) Potential Application of Measuring Serum Infliximab Levels in Rheumatoid Arthritis Management: A Retrospective Study based on KURAMA Cohort Data (日)
| [継承] |
| ○副題 (任意): |
| ○要約 (任意): | □ | (英) Infliximab (IFX) therapy has considerably improved the treatment of rheumatoid arthritis (RA). However, some patients still do not respond adequately to IFX therapy, or the efficacy of the treatment diminishes over time. Although previous studies have reported a relationship between serum IFX levels and therapeutic efficacy, the potential applications of IFX therapeutic drug monitoring (TDM) in clinical practice remain unclear. The purpose of this study was to investigate the potential applications of IFX TDM by analyzing a Japanese cohort database. Data were collected retrospectively from the Kyoto University Rheumatoid Arthritis Management Alliance cohort between January 1, 2011, and December 31, 2018. Serum IFX levels were measured using a liquid chromatography-tandem mass spectrometer. Out of the 311 RA patients that used IFX, 41 were eligible for the analysis. Serum IFX levels were significantly higher in responders than in non-responders. An optimal cut-off value was determined to be 0.32 μg/mL based on a receiver operating characteristic curve. At the IFX measurement point, a better therapeutic response was observed in the high IFX group (n = 32) than in the low IFX group (n = 9). Conversely, at the maximum effect point, when DAS28-ESR was the lowest between IFX introduction and measurement points, there were no differences in responder proportions between the low and high IFX groups. IFX primary ineffectiveness could be avoided with appropriate dose escalation without blood concentration measurement in clinical practice. In conclusion, IFX TDM could facilitate the identification of secondary non-responders and in turn, proper IFX use. (日)
| [継承] |
| ○キーワード (推奨): | 1. | (英) Infliximab (日) (読)
| [継承] |
| 2. | (英) Rheumatoid Arthritis (日) (読)
| [継承] |
| 3. | (英) KURAMA Cohort (日) (読)
| [継承] |
| ○発行所 (推奨): |
| ○誌名 (必須): | □ | PLoS ONE (Public Library of Science)
(eISSN: 1932-6203)
| ○ISSN (任意): | □ | 1932-6203
ISSN: 1932-6203
(eISSN: 1932-6203) Title: PloS oneTitle(ISO): PLoS OnePublisher: PLOS (NLM Catalog)
(Scopus)
(CrossRef)
(Scopus information is found. [need login]) | [継承] |
| [継承] |
| ○巻 (必須): | □ | 16
| [継承] |
| ○号 (必須): | □ | 10
| [継承] |
| ○頁 (必須): | □ | e0258601 e0258601
| [継承] |
| ○都市 (任意): |
| ○年月日 (必須): | □ | 西暦 2021年 10月 13日 (令和 3年 10月 13日)
| [継承] |
| ○URL (任意): |
| ○DOI (任意): | □ | 10.1371/journal.pone.0258601 (→Scopusで検索)
| [継承] |
| ○PMID (任意): | □ | 34644354 (→Scopusで検索)
| [継承] |
| ○CRID (任意): |
| ○WOS (任意): |
| ○Scopus (任意): |
| ○評価値 (任意): |
| ○被引用数 (任意): |
| ○指導教員 (推奨): |
| ○備考 (任意): | 1. | (英) Article.ELocationID: 10.1371/journal.pone.0258601 (日)
| [継承] |
| 2. | (英) Article.PublicationTypeList.PublicationType: Journal Article (日)
| [継承] |
| 3. | (英) CoiStatement: M.H., R.W., K.Murata, M.T., and H.I. are associated with a department financially supported by two local governments in Japan (Nagahama City, Shiga and Toyooka City, Hyogo) and five pharmaceutical companies (Mitsubishi Tanabe Pharma Corp., Chugai Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corp., Asahi Kasei Pharma Corp., and UCB Japan Co., Ltd.). A.Y. and K.Matsubara has received a research grant from Shimadzu Corporation. M.H. received a research grant and/or speaker fee from Bristol-Myers Squibb Co., Eisai Co., Ltd., Eli Lilly Japan K.K., and Mitsubishi Tanabe Pharma Corp. R.W. has received speaker's fee from Mitsubishi Tanabe Pharma Corp., Pfizer Inc., Sanofi K.K., AbbVie GK, Asahi-Kasei Corp., Eisai Co., Ltd., Eli Lilly Japan K.K., Bristol-Myers Squibb Co., and Janssen Pharmaceutical K.K. K.Murata received a speaking fee from Eisai Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Astellas Pharma Inc. M.T. has received research grants and/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Corp., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K., Pfizer Inc., Taisho Pharma Co., Ltd., and UCB Japan Co., Ltd. H.I. has received a research grant and/or speaker fees from Bristol-Myers Squibb Co., Eisai Co., Ltd., Taisho Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Asahi Kasei Corp. The other authors declare no conflicts of interest. (日)
| [継承] |